ARHEX | VLXVX | ARHEX / VLXVX | |
Total Expense Ratio | 1.89 | 0.08 | 2,363% |
Annual Report Gross Expense Ratio | 1.95 | 0.08 | 2,438% |
Fund Existence | 5 years | 8 years | - |
Gain YTD | 7.239 | 10.738 | 67% |
Front Load | N/A | N/A | - |
Min. Initial Investment | 2500 | 1000 | 250% |
Min. Initial Investment IRA | N/A | N/A | - |
Net Assets | 141M | 11.4B | 1% |
Annual Yield % from dividends | 0.89 | 1.88 | 47% |
Returns for 1 year | 9.83 | 12.63 | 78% |
Returns for 3 years | 33.48 | 46.26 | 72% |
Returns for 5 years | N/A | 62.36 | - |
Returns for 10 years | N/A | N/A | - |
1 Day | |||
---|---|---|---|
MFs / NAME | Price $ | Chg $ | Chg % |
DIEAX | 43.36 | 0.40 | +0.93% |
BNY Mellon International Core Equity A | |||
NARCX | 65.97 | 0.52 | +0.79% |
Voya Multi-Manager International Sm Cp C | |||
SCWCX | 59.10 | 0.41 | +0.70% |
American Funds SMALLCAP World C | |||
GSEUX | 68.84 | 0.41 | +0.60% |
Goldman Sachs US Equity Insights R6 | |||
FBIOX | 18.40 | N/A | N/A |
Fidelity Select Biotechnology |